After push to remove artificial coloring, FDA approves 3 natural food dyes
The US Food and Drug Administration has approved three new color additives from natural sources 'that will expand the palette of available colors from natural sources for manufacturers to safely use in food,' the agency said in a news release.
The three dyes are Galdieria extract blue, butterfly pea flower extract and calcium phosphate.
US Department of Health and Human Services Secretary Robert F. Kennedy Jr. has made phasing out petroleum-based dyes in the nation's food supply one of the priorities in his broader initiative to 'Make America Healthy Again.'
Artificial food dyes are facing new restrictions or bans at both the federal level and in more than half the states. In April, FDA Commissioner Dr. Marty Makary announced the agency would work with the industry to remove and replace the dyes, though the FDA largely hasn't yet made this a requirement for industry.
'For too long, our food system has relied on synthetic, petroleum-based dyes that offer no nutritional value and pose unnecessary health risks,' Kennedy said in a news release. 'We're removing these dyes and approving safe, natural alternatives — to protect families and support healthier choices.'
Galdieria extract blue derives from Galdieria sulphuraria, a type of red algae that carries a water-soluble blue pigment known as C-Phycocyanin and is found in acidic volcanic hot springs and calderas, according to the FDA and Fermentalg, a French chemical company using micro-algae for colorants, foods and supplements.
Fermentalg sought approval for the additive for foods and beverages via a petition it submitted to the FDA in 2021 and has patented a Galdieria sulphuraria extract under the name Everzure.
Galdieria sulphuraria's natural ability to reside in acidic environments lends to its stability in food and beverages, which is something food and beverage manufacturers have been concerned about in the shift to natural alternatives to highly stable artificial dyes.
Butterfly pea extract is a blue color from which manufacturers can create a range of shades including bright blues, intense purples and natural greens, according to the FDA. It's produced from the water extraction of the dried flower petals of the butterfly pea plant, and is already approved for some uses, including sports drinks, fruit drinks, fruit and vegetable juices, alcoholic beverages, candy and ice creams.
Its use is now expanded to also include ready-to-eat cereals, crackers, snack mixes, hard pretzels, plain potato chips, plain corn chips, tortilla chips and multigrain chips, the FDA said. The petition that raised this extract for consideration was submitted in February 2024 by the St. Louis-based Sensient Colors, one of the largest global dye-makers.
Calcium phosphate, a mineral compound containing both calcium and phosphorus, provides a white color newly approved for use in ready-to-eat chicken products, white candy melts, doughnut sugar and sugar for coated candies, according to the FDA, whose decision approves a 2023 petition filed by New Jersey-based Innophos Inc., a mineral solutions company.
'The FDA determines whether an additive is safe to use by considering the projected human dietary exposure to the color additive, the additive's toxicological data, and other relevant information, such as published literature,' the agency stated in a news release.
The embrace of natural dyes is due to health concerns around artificial colorants, such as increased risk of cancer and neurobehavioral issues. While some manufacturers acknowledge these concerns, they have also highlighted the challenges involved in an industrywide shift to alternative dyes, which is likely due to both state-level bans and the FDA's requirement that food companies remove red dye No. 3 — banned in January — from foods by January 15, 2027.
'Natural colors can be more expensive from a cost-in-use perspective depending on the raw ingredient being used,' Amy Agallar, vice president of investor relations and treasurer at Sensient, said via email May 2. 'The raw ingredients can vary due to many factors such as availability, time to harvest and color availability from the raw material. The natural color needed to replace a synthetic color can be ten times that of a synthetic product.'
That discrepancy is partly due to some food and beverage products requiring heat processing or acids that affect the stability of natural colors, Agallar added. 'Some natural colors are also not very light stable and this may be needed in the end application.'
Additionally, 'studies show that customers prefer products with color and are more likely to purchase food and beverages with a color that matches the expected flavor,' Agallar said. 'Consumers use the color to identify how a product will taste. Food manufacturers currently use natural color products in about 80% of new colored food and beverages released in the US each year.'
There's little funding for research on artificial food dyes, and even less for the study of emerging alternatives — so it's not yet known whether these new natural dyes could have any effect on human health. But with most natural dyes coming from plants and being used in small quantities, 'it's hard to believe they'd have any effect' on the general population, Dr. Marion Nestle, Paulette Goddard Professor of Nutrition, Food Studies, and Public Health, Emerita, at New York University, told CNN in a previous story.
Sensient has developed its own safety program, Certasure, Agallar said. 'This program ensures that our natural colors are free of pesticides, heavy metals, microbiological contamination, adulteration, and unauthorized solvents.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA determination that NRX-100 has the potential to address an unmet need, based on FDA's assessment of the data submitted Determination of "unmet need" is a requirement for a Commissioner's National Priority Voucher (CNPV) program. Suicide is a public health crisis. Approximately 13 million adults seriously consider suicide each year, according to the CDC, 3.7 million make a plan to commit suicide. An American dies from suicide every 11 minutes. Active-duty personnel, veterans, and first responders have a four-fold higher risk of suicide. WILMINGTON, Del., Aug. 11, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced US Food and Drug Administration (FDA) has granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. This designation for NRX-100 as a standalone drug is a 10-fold expansion of the addressable population for NRX-100, compared to the designation granted in 2017 for NRX-100 in combination with NRX-101 (DCS/lurasidone) for treatment of Suicidal Bipolar Depression. In granting the Fast Track designation, FDA made the determination that NRX-100 has the potential to address an unmet medical need, based on an assessment of the preliminary data contained in the Fast Track designation request. This determination of unmet medical need aligns with the eligibility requirements for the Commissioner's National Priority Voucher Program (CNPV)i and for the FDA's Accelerated Approval The Company has applied for a CNPV, which has the potential to substantially shorten the review cycle for NRX-100. Several well-controlled trials submitted to FDA in support of Fast Track Designation demonstrated a clinically meaningful and statistically significant reduction of suicidal ideation. In a Columbia University study licensed by NRx, suicidal patients treated with intravenous ketamine demonstrated a 55% response (i.e. 50% reduction in suicidality) compared to a 30% response to active comparator (P<.02).iii In a trial sponsored by the Government of France and licensed by NRx, 63% of patients achieved full remission from suicidal ideation in three days compared to 31% of those who received placebo (P<.001). This effect has not been proven with intranasal administration of "We thank FDA for its thoughtful review of our Fast Track designation request, and believe this regulatory determination is a significant step forward in our goal to address the national crisis of suicide among soldiers, first responders, veterans, and civilians alike." said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals. "Large-scale government-supported trials have demonstrated a robust and statistically significant reduction in suicidal ideation and depression with administration of ketamine. This drug was also proven to be non-inferior to electroshock therapy in treating depression without the negative side effects of ECT. We look forward to working closely with the FDA in our quest to Bring Hope to Life." Under the terms of the Fast Track program, NRx will be posting an expanded access policy for NRX-100 in the next two weeks and seeking a meeting with FDA leadership to finalize the data to be submitted under the Accelerated Approval / CNPV application. In addition to the benefits above, Fast Track Designation also grants enhanced communication with the FDA, as well as potential Priority Review and Rolling Review. NRX-100 in Suicidal Ideation in Patients with Depression, Including Bipolar Depression According to the CDC, approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – is designed to help address this national crisis. NRx will be submitting patient-level data from controlled clinical trials that demonstrate ketamine to be superior to both a placebo and an active comparator, as well as either non-inferior or superior to electroshock therapy in treating various forms of depression, including patients with active suicidal ideation. Although ketamine in various forms is increasingly used to treat depression and related disorders, it is currently only approved by FDA only for use as an anesthetic and, therefore, not reimbursed by most insurance carriers for treatment of suicidality or depression. Intravenous ketamine is reimbursed by the Department of Veterans Affairs and the Department of Defense for its beneficiaries. By applying for FDA labeling for NRX-100 to treat suicidal depression, the Company hopes to make this potentially life-saving therapy available to all Americans, not just those who are able to pay out of pocket. The Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preservative-free ketamine. Having completed this Fast Track Designation, NRx is now filing draft labeling for NRX-100 to comply with the CNPV requirement. NRX-100 is the first preservative-free presentation of ketamine to be filed with FDA. Currently available product, primarily of foreign manufacture, contains a known toxic preservative, Benzethonium Chloride (BZT) that is not Generally Recognized as Safe (GRAS) and is not allowed by FDA to be used in hand cleaners and topical antiseptics. NRx demonstrated long term stability and sterility with its patented preservative-free formulation of NRX-100. The Company has additionally filed a Citizen Petition seeking to have BZT removed from all intravenous ketamine products. The Company has instituted US-based high-volume manufacture of sterile, preservative-free ketamine. Regarding Fast Track designation, FDA's website states: A drug that receives Fast Track designation is eligible for some or all of the following: More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval. More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met. Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. References i Grunebaum, et al. Ketamine for rapid reduction of suicidal thoughts… Am J Psychiatry 2018;175: Abbar, et al. Ketamine for the acute treatment of severe suicidal ideation… BMJ 2021;167:194-203 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals mduffy@ Brian Korb Managing Partner (917) 653-5122 View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
2 hours ago
- Business Wire
Elucid's PlaqueIQ ™ Image Analysis Software Now Covered by United Healthcare
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced that United Healthcare has updated its cardiac imaging guidelines to fully align with recent recommendations from radiology benefit manager EviCore. United Healthcare's new guidelines now include coronary computed tomography angiography (CTA) plaque quantification (see page 520), specifically encompassing Elucid's PlaqueIQ™ technology. The coverage will apply to all United Healthcare plans beginning October 1, 2025. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology. PlaqueIQ delivers automated quantification and classification of plaque morphology, and is uniquely capable of identifying and quantifying lipid rich necrotic core, a plaque type strongly linked with cardiovascular risk. 1,2 The software is designed to help physicians prioritize and personalize treatment based on actual coronary artery disease, rather than population-based risk. This technology supports physicians in evaluating treatment of patients' symptoms and risk of future cardiac events, such as heart attack and stroke, and enables the development of personalized care pathways informed by each patient's individual plaque characteristics. 'United Healthcare's new e guidelines further underscore the need for better tools to help clinicians get ahead of heart attack and stroke,' said Elucid CEO Kelly Huang, PhD. 'With its basis in CT Virtual Histology™, we believe that PlaqueIQ is poised to make a meaningful difference towards this goal.' United Healthcare's updated guidelines align with recently issued guidelines by radiology benefit manager EviCore. In addition to the recent coverage decision by United Healthcare, a new CMS rule went into effect on January 1, 2025, which doubled the amount paid to hospitals and outpatient clinics who perform cardiac CT scans from $175 to $357.13. This has allowed more hospitals, particularly those in non-urban areas, to be able to offer this service, reducing disparities in care. In late 2024, five of the seven Medicare Administrative Contractors (MACs) issued decisions to extend coverage of Elucid's PlaqueIQ, making it available to over 70 percent of eligible Medicare patients across the United States. The newly assigned Category I code for coronary plaque analysis, which goes into effect on January 1, 2026, complements the recent coverage decisions by United Healthcare and EviCore, allowing for expanded patient access and personalized treatment for patients with coronary artery disease (CAD). About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit


Atlantic
2 hours ago
- Atlantic
Are You Cowmaxxing?
A not-insignificant number of TikToks aim to convince the viewer that beef-tallow moisturizer will not make your face smell like a cow. The beauty influencers who tend to appear in these videos—usually clear-skinned women rubbing tallow into their face as they detail their previous dermatological woes—describe the scent as 'buttery' or 'earthy' or grass-like. Many of them come to the same conclusion: Okay, even if the tallow does smell a little bit, the smooth skin it leaves behind is well worth it. Beef tallow (as both a moisturizer and an alternative to seed oils) is one of many cow-based products that have crowded the wellness market in the past five or so years. Beef-bone broth is a grocery-store staple. Demand for raw milk has grown, despite numerous cases of illness and warnings from public-health officials that drinking it can be fatal. In certain circles, raw cow organs—heart, liver, kidney—are prized superfoods. Target and Walmart sell supplements containing bovine collagen (a protein found in cowhide and bone) and colostrum (the rich liquid that mammals produce for their newborn offspring); they promise healthier skin, a happier gut, and stronger immunity, and come in flavors such as watermelon lime, lemon sorbet, and 'valiant grape.' You can buy cow-placenta pills for postpartum healing, or powdered bull testicle for testosterone support. The slightest interaction with clean-beauty Instagram can fill your feed with ads for beef-tallow lip balms, cleansing creams, sunscreen, and deodorants. (One brand even offers creamsicle-flavored beef-tallow personal lubricant, which is currently out of stock online.) Influencers praise tallow for clearing their acne and eczema—and offer discount codes so you can experience the same. Even the government's recent public-health messaging has veered toward the bovine. During his tenure as health secretary, Robert F. Kennedy Jr. has championed cooking in beef tallow (which he says is healthier than seed oils) and drinking raw milk (one of many items that he claims are suppressed by the FDA). Casey Means, President Donald Trump's nominee for surgeon general, also supports raw milk; she has suggested that Americans can decide whether a given bottle is safe to drink by looking the dairy farmer in the eye and petting his cow. Means and Kennedy have largely avoided engaging with the many public-health experts who reject their views. But in May, after months of such critiques, Kennedy took shots of raw milk at the White House to celebrate the release of the 'Make America Healthy Again' report. Woo-woo, it seems, is becoming moo-moo. America has entered its cowmaxxing era. Like most wellness offerings, cow products are marketed with vague health claims that are virtually impossible to confirm or deny, such as 'deeply nourishes and supports the skin barrier,' 'activate cellular health,' and 'supports memory.' One of the many promises of the Ancestral Supplements Starter Pack of organ-based capsules is simply 'vitality.' (The company also includes a disclaimer that the FDA has not reviewed said vitality benefits.) Advocates of these goods tend to be more specific in their praise. Raw-milk enthusiasts claim that unpasteurized milk contains bioactive chemicals that improve human health. In one video, a woman drinks raw milk that's been in the fridge for more than a month; she claims it is safer to consume than store-bought pizza or salad and that it reduces rates of eczema, fevers, and respiratory infections. One smooth-skinned influencer, who says she hasn't washed her face in two years, claims that beef tallow is 'bioidentical' to the sebum produced by human skin. (It's not, because it's from cows.) Some of these products are more likely to provide benefits than others. Bone broth is indeed rich in collagen (which, when produced by the human body, strengthens hair and skin). Whey powder, made from leftover cheese water, does contain protein. But very few studies support the idea that eating more collagen strengthens hair and skin. Whey protein can help build lean muscle, but the body can only absorb so much at a time. Some dermatologists say tallow can strengthen and hydrate the skin; others say it clogs pores and should be avoided. Other products can be downright dangerous: Just this week, Florida officials announced that 21 people fell sick after consuming contaminated raw milk. At least part of the appeal of cowmaxxing is the cows themselves: The products evoke the pastoral ideal of a cow grazing freely in the plains, milked lovingly by human hands. It's an image that's been embedded in American culture for centuries. Consider how Laura Ingalls Wilder, who was no stranger to the harsh reality of farm life, described cow-raising in Little Town on the Prairie: 'Warm and sweet, the scent of new milk came up from the streams hissing into the rising foam, and it mixed with the scents of springtime.' It's enough to persuade a microbiologist to drink raw milk. In 21st-century America, cows still summon images of fields and clover and wide blue sky, enough to trigger the human tendency to believe that what's natural is 'fundamentally good,' Courtney Lappas, a biology professor at Lebanon Valley College, told me. Her research has shown that some Americans prefer natural over man-made products even when the former is described as objectively worse—a phenomenon her colleague Brian Meier has called the 'naturalness bias.' This tendency, which is prevalent across cultures, likely leads people to assume that unprocessed cow-based products are safe and healthy, she said. Tallow, some skin-care enthusiasts claim, is a healthier, safer alternative to conventional moisturizers, which supposedly contain toxic chemicals. The branding of such products, too, leans into the notion that natural is best: Fat Cow Skincare markets its tallow cosmetics as 'pure skincare, powered by nature'; Heart and Soil sells capsules of 'nature's superfood' (that is, organ meats). Other brands invoke nature through the prehistoric, with names such as Primal Harvest, Primal Kitchen, Primal FX, Primal Being, and Primal Queen. Ancestral Supplements' ad copy reads: 'Putting Back In What the Modern World Left Out.' America's current health landscape is the perfect setting for cowmaxxing to thrive. The naturalness bias is deeply ingrained in Kennedy's MAHA campaign, which aims to improve public health by returning to a more natural lifestyle. In Kennedy's view, beef tallow is superior to seed oil because it's less processed (some people even render it at home). The carnivore and tradwife movements embody a similar message, promoting the consumption of raw cow organs and making butter from scratch. You may not know what's in store-bought products, the thinking goes, but you do know what's in tallow: pure, unadulterated cow fat. And yet most modern cows live in a decidedly unnatural environment. The majority of U.S. cattle are fed genetically modified crops, and some genetically modified cows are allowed to be sold as food. Many cow-based wellness products bear the label 'grass-fed,' which suggests cows that were raised on pastures rather than feedlots. But the label is not strictly enforced, and it doesn't necessarily prohibit farmers from giving cows antibiotics or hormones. There's no guarantee that a cow whose colostrum is harvested to be sold by a tradwife on Instagram had a happy, bucolic existence. Not to mention that colostrum, whey, and placenta do not come out of the cow in the form of powders or pills. The spread of science misinformation, along with legitimate concerns about the state of public health in the United States, have left many Americans understandably confused about whether conventional science and Western medicine can be trusted in 2025. Getting to the bottom of, say, the seed-oil controversy requires engaging with thorny scientific debates that reference inscrutable research papers; embracing the natural and ancestral by opting for tallow is an attractively simple-seeming alternative. 'It brings with it a sense of purity or wholesomeness that is desirable right now,' Marianne Clark, a sociologist at Acadia University who studies wellness trends, told me. In this sense, cowmaxxing is not so much a health endeavor as it is a spiritual one, its promise downright biblical: Cowliness is next to godliness.